Real-World Data and Impact on Treatment Selection in uHCC

This is a video synopsis/summary of a Post-Conference Perspectives featuring Anwaar Saeed, MD, and Amit Singal, MD, MS.

Singal and Saeed emphasize the importance of real-world data to address questions that prospective clinical trials cannot, including head-to-head regimen comparisons and outcomes in patient subgroups excluded from trials. Saeed discusses a small 28-patient study of atezolizumab-bevacizumab showing a median overall survival of 11 months, lower than the 19 months seen in IMbrave150. However, she cautions this early real-world analysis is too limited to draw conclusions against atezolizumab-bevacizumab efficacy and notes the heterogeneity underlying variation.

Singal agrees, highlighting how real-world cohorts often differ substantially from clinical trial populations, which select for high-performance status patients. He references the larger AB-Real study of 430 patients receiving first-line atezolizumab-bevacizumab, which showed a median survival of 15.7 months. While numerically lower, this effectiveness data is not meaningfully inferior to the trial efficacy findings. Reassuringly, safety seems consistent between the clinical trial and real-world utilization. Both physicians feel that atezolizumab-bevacizumab retains compelling efficacy and safety. Looking ahead, analyses of larger real-world cohorts can better define outcomes in excluded subgroups and help guide treatment decisions.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.